DNA SEC Filings: 8-K, 10-Q, S-3 & 424B – Ginkgo Bioworks

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Ginkgo Bioworks Reports Third Quarter 2026 Results and Autonomous Lab Expansion

Nov 5, 2026

8-K

Ginkgo Bioworks Schedules Third Quarter 2026 Results Presentation for November 5, 2026

Oct 29, 2026

8-K

Ginkgo Bioworks Reports Q2 2026 Results and Secures Government Contracts for Autonomous Labs

Aug 5, 2026

8-K

Ginkgo Bioworks Announces Date for Second Quarter 2026 Financial Results

Jul 30, 2026

8-K

Ginkgo Bioworks Holdings, Inc. Announces Results of 2026 Annual Meeting of Shareholders

Jun 12, 2026

8-K

Ginkgo Bioworks Reports Q1 2026 Financial Results and Completes Biosecurity Divestiture

May 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

September 2025 ATM

Sep 4, 2025

424B3

18,857,026 Shares of Class A common stock

May 17, 2024

424B3

5,283,679 Shares of Class A common stock

Aug 29, 2023

424B3

7,279,426 Shares of Class A Common Stock

Feb 3, 2023

424B5

41,383,877 Shares

Nov 17, 2022

424B5

Class A Common Stock

Nov 15, 2022

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2026

S-3

August 2025 SHELF

Aug 7, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 25, 2025

S-3

18,857,026 Shares of Class A common stock EFFECTIVE

May 9, 2024

S-8

Registration

Feb 29, 2024

S-3

5,283,679 Shares of Class A common stock

Aug 23, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Aug 9, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 5, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Coen Steven P. (Reporting)

Oct 21, 2026

Canton Barry (Reporting)

Oct 21, 2026

Shetty Reshma P. (Reporting)

Oct 21, 2026

Kelly Jason R (Reporting)

Oct 21, 2026

144

Form 144 - Report of proposed sale of securities

Oct 19, 2026

144

Form 144 - Report of proposed sale of securities

Oct 19, 2026

Other

TYPE

HEADLINE

FILED AT

Ginkgo Bioworks Holdings, Inc. DNA · SEC Filings